IN8BIO, INC. Repayments of Debt
IN8BIO, INC. (INAB) reported Repayments of Debt of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-30.
Discontinued › Cash Flow › Financing Activities
us-gaap:RepaymentsOfDebt · last filed 2023-03-30
- IN8BIO, INC. repayments of debt for the quarter ending 2022-12-31 was $0.00.
- IN8BIO, INC. repayments of debt for the quarter ending 2021-12-31 was $0.00.
- IN8BIO, INC. repayments of debt for the quarter ending 2020-12-31 was $0.00.
- IN8BIO, INC. repayments of debt for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- IN8BIO, INC. repayments of debt for fiscal 2021 was $174.00K.
- IN8BIO, INC. repayments of debt for fiscal 2020 was $0.00.
| Period end | Repayments of Debt 3 month | Repayments of Debt 9 month | Repayments of Debt 12 month |
|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $0.00 10-K · filed 2023-03-30 | |
| 2022-09-30 | $0.00 10-Q · filed 2022-11-10 | ||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $174.00K 10-K · filed 2023-03-30 | |
| 2021-09-30 | $174.00K 10-Q · filed 2022-11-10 | ||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $0.00 10-K · filed 2022-03-17 | |
| 2020-09-30 | $0.00 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| Pluri Inc. (PLUR) | $0.014B | ||
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B |